Relay Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Relay Therapeutics

06/08/2026 22:39

Relay Therapeutics, Inc. RLAY.OQ reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The mean expectation of fourteen analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -45 cents to -33 cents per share.
Revenue fell 48.3% to $350.00 thousand from a year ago; analysts expected $872.73 thousand. 
Relay Therapeutics, Inc.'s reported EPS for the quarter was a loss of 41 cents​.
The company reported a quarterly loss of $83.71 million.
Relay Therapeutics, Inc. shares had risen by 5.2% this quarter and gained 132.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Relay Therapeutics, Inc. is $26.50, about 25.7% above its last closing price of $19.69
This summary was machine generated from LSEG data August 6 at 09:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.39
-0.41
Missed
Mar. 31 2026 
-0.38
-0.41
Missed
Dec. 31 2025 
-0.40
-0.32
Beat
Sep. 30 2025 
-0.42
-0.43
Missed